Haleon Pakistan Limited has announced the commencement of manufacturing Panadol 500mg tablets at its Jamshoro facility, marking a significant step in enhancing its production capabilities.
- The in-house manufacturing follows a prior investment announced on 13 October 2023.
- The new tablets will feature a redesigned engraving, replacing the existing "Panadol" text while maintaining product quality.
- This initiative aims to strengthen the company's manufacturing capabilities and ensure reliable product availability for consumers in Pakistan.
- The transition to in-house production is expected to bolster the company's market position.